LPP antisense RNA 2 (LPP-AS2)

LPP antisense RNA 2 is a long non-coding RNA that acts as a molecular regulator in cancer. It is directly modulated by the MYC transcription factor and participates in cancer cell proliferation and survival through cellular pathways including the EGFR/PI3K/AKT/c-MYC loop. LPP-AS2 can function as a competitive endogenous RNA (ceRNA), sponging microRNAs such as miR-7-5p, thereby upregulating EGFR and promoting malignant progression. In colorectal cancer and related malignancies, its repression by MYC and involvement with cell cycle-related genes indicate its regulatory significance in oncogenesis. Elevated LPP-AS2 expression is robustly associated with poor prognosis in glioma and supports its candidacy as a diagnostic and therapeutic target.\n\nIn summary, LPP antisense RNA 2 (LPP-AS2) is a validated long non-coding RNA implicated in the regulation of cancer biology, considered a promising RNA-based therapeutic and biomarker target, particularly in glioma and MYC-driven cancers.

Other names

MYCLo-5MYCLo-6LPP-AS2FLJ42393

Therapeutic targeting potentially involves: RNA interference (RNAi)\nAntisense oligonucleotides\nModulation of ceRNA interactions (e.g., via miR-7-5p/EGFR axis)